Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

ABSTRACT: This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.

DISEASE(S): Ovarian Cancer,Sarcoma,Nsclc,Colorectal Cancer,Advanced Solid Tumors,Mesothelioma,Cancer

PROVIDER: 2049746 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR